Last reviewed · How we verify
NCT06703450
Guerbet Liver Fibrosis
trial in Metabolic Dysfunction-associated Steatotic Liver Disease in 50 participants. Enrolling by invitation.
28 February 2026
Quick facts
| Lead sponsor | Icahn School of Medicine at Mount Sinai |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 28 February 2024 |
| Primary completion | 28 February 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United States |
Conditions studied
- Metabolic Dysfunction-associated Steatotic Liver Disease — all drugs for Metabolic Dysfunction-associated Steatotic Liver Disease →
Sponsor
Icahn School of Medicine at Mount Sinai
Who can join
Adults 18 to 89, any sex, with Metabolic Dysfunction-associated Steatotic Liver Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to assess the value of liver dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and texture analysis post gadopiclenol for liver fibrosis staging, in comparison with MR elastography, T1 mapping, ultrasound elastography and blood tests in 50 initial patients with metabolic dysfunction-associated steatohepatitis (MASH).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06703450
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Metabolic Dysfunction-associated Steatotic Liver Disease
Currently open trials in the same condition.
- NCT06619808 — Hyperbaric Oxygen Therapy for Metabolic Dysfunction-associated Steatotic Liver Diseases · NA · recruiting
- NCT06465186 — A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017) · Phase 2 · active not recruiting
- NCT06495333 — Fecal Microbiota Analysis of PNPLA3 Polymorphism in Hispanic Patients With MASLD · recruiting
- NCT06359444 — Effect of High Intensity Exercise Rehabilitation on Liver Function and Insulin Sensitivity in Patients With MASLD · NA · recruiting
- NCT07083336 — Liver Fat as a Dietary Target of the Chinese Medical Nutrition Therapy (CMNT) Diet for Treating Type 2 Diabetes With Non · NA · recruiting
Other Icahn School of Medicine at Mount Sinai trials
Trials by the same sponsor.
- NCT07094308 — The LIFT-ECHO Last Mile Project · NA · not yet recruiting
- NCT07291427 — Chronic Subdural Hematoma Embolization With Detachable Coils · not yet recruiting
- NCT07194187 — High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction · NA · not yet recruiting
- NCT07260916 — Minimally Invasive Neuroendoscopic Ultra-Early Targeted ICH Evacuation · NA · not yet recruiting
- NCT07487948 — Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06703450 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Icahn School of Medicine at Mount Sinai
- Last refreshed: 28 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06703450.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing